{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:21Z","timestamp":1791685341368,"version":"4.3.4"},"reference-count":45,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100247"],"award-info":[{"award-number":["82100247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["2024A30"],"award-info":[{"award-number":["2024A30"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["24-2KYC13060-23"],"award-info":[{"award-number":["24-2KYC13060-23"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for certain hematologic malignancies, therapeutic resistance and disease relapse highlight the critical need to improve the durability of clinical responses. The limited in vivo persistence and antitumor efficacy of CAR-T cells remain major barriers to achieving sustained therapeutic outcomes. Although CD5 has been extensively studied as a therapeutic target in cancers, particularly T-cell malignancies, its role as an immunomodulatory molecule in T cell-based immunotherapy remains poorly understood. Here, we developed a CD5-deficient T cell-based immunotherapy using the CRISPR-Cas9 system to address these limitations and enhance antitumor potency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Employing green fluorescent protein knock-in murine models alongside clinical specimens, we examined the in vivo persistence of CD5-deficient T cells and their influence on T-cell receptor (TCR) clonality diversity. The antitumor efficacy of CD5-deficient engineered T cells was assessed in tumor cell line-derived xenograft murine models. To elucidate underlying mechanisms, we performed a comprehensive evaluation of the activation, expansion and infiltration of CD5-deficient engineered T cells in response to antigen stimulation, as well as their exhaustion dynamics under conditions of repeated antigen exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our study identifies CD5 as a bona fide inhibitory immunomodulatory molecule. CD5 ablation significantly enhances T cell functionality by enhancing the activation level, mitigating exhaustion, promoting CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell expansion, and improving in vivo persistence. Single-cell transcriptomic profiling of patient-derived CD5-deficient T cells revealed distinct effector subsets with elevated cytotoxicity markers and cell cycle regulators, such as STMN1, which correlate with enhanced expansion while preserving clonal diversity, as evidenced by TCR repertoire analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These collective findings establish CD5 ablation as a viable strategy to circumvent the intrinsic limitations of current T cell-based therapies, providing a mechanistic rationale for clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012243","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T04:55:20Z","timestamp":1764478520000},"page":"e012243","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04767308","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-3644","authenticated-orcid":false,"given":"Jia","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weini","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Cedars-Sinai Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"An","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-6344","authenticated-orcid":false,"given":"Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7903-7459","authenticated-orcid":false,"given":"Wei","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"2026091123004090000_13.11.e012243.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2026091123004090000_13.11.e012243.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026091123004090000_13.11.e012243.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"key":"2026091123004090000_13.11.e012243.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026091123004090000_13.11.e012243.5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-204355","article-title":"Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed\/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"2026091123004090000_13.11.e012243.6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature New Biol"},{"key":"2026091123004090000_13.11.e012243.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0480-4"},{"key":"2026091123004090000_13.11.e012243.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.001"},{"key":"2026091123004090000_13.11.e012243.9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature New Biol"},{"key":"2026091123004090000_13.11.e012243.10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/323346a0","article-title":"Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1","volume":"323","author":"Jones","year":"1986","journal-title":"Nature New Biol"},{"key":"2026091123004090000_13.11.e012243.11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100301.064833"},{"key":"2026091123004090000_13.11.e012243.12","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22841","article-title":"T-cell modulatory properties of CD5 and its role in antitumor immune responses","volume":"2","author":"Tabbekh","year":"2013","journal-title":"Oncoimmunology"},{"key":"2026091123004090000_13.11.e012243.13","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg2752","article-title":"CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses","volume":"379","author":"He","year":"2023","journal-title":"Science"},{"key":"2026091123004090000_13.11.e012243.14","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0618-226R"},{"key":"2026091123004090000_13.11.e012243.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"2026091123004090000_13.11.e012243.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.003"},{"key":"2026091123004090000_13.11.e012243.17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1515\/med-2018-0089","article-title":"CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients","volume":"13","author":"Huang","year":"2018","journal-title":"Open Med (Wars)"},{"key":"2026091123004090000_13.11.e012243.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026091123004090000_13.11.e012243.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.07.001"},{"key":"2026091123004090000_13.11.e012243.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00144-2"},{"key":"2026091123004090000_13.11.e012243.21","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.molonc.2015.03.010","article-title":"Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma","volume":"9","author":"Oden","year":"2015","journal-title":"Mol Oncol"},{"key":"2026091123004090000_13.11.e012243.22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"2026091123004090000_13.11.e012243.23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178572","article-title":"Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells","volume":"10","author":"Cheng","year":"2025","journal-title":"JCI Insight"},{"key":"2026091123004090000_13.11.e012243.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.015"},{"key":"2026091123004090000_13.11.e012243.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.035"},{"key":"2026091123004090000_13.11.e012243.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0032-3"},{"key":"2026091123004090000_13.11.e012243.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5"},{"key":"2026091123004090000_13.11.e012243.28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945"},{"key":"2026091123004090000_13.11.e012243.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112663"},{"key":"2026091123004090000_13.11.e012243.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.04.022"},{"key":"2026091123004090000_13.11.e012243.31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/imm.13642","article-title":"T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it","volume":"169","author":"Yin","year":"2023","journal-title":"Immunology"},{"key":"2026091123004090000_13.11.e012243.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.013"},{"key":"2026091123004090000_13.11.e012243.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2026091123004090000_13.11.e012243.34","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-023-00450-x","article-title":"CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2026091123004090000_13.11.e012243.35","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2026091123004090000_13.11.e012243.36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"key":"2026091123004090000_13.11.e012243.37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn6509","article-title":"CD5 deletion enhances the antitumor activity of adoptive T cell therapies","volume":"9","author":"Patel","year":"2024","journal-title":"Sci Immunol"},{"key":"2026091123004090000_13.11.e012243.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.7542801"},{"key":"2026091123004090000_13.11.e012243.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100854"},{"key":"2026091123004090000_13.11.e012243.40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.6888"},{"key":"2026091123004090000_13.11.e012243.41","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"2026091123004090000_13.11.e012243.42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/35019102","article-title":"CD3delta couples T-cell receptor signalling to ERK activation and thymocyte positive selection","volume":"406","author":"Delgado","year":"2000","journal-title":"Nature New Biol"},{"key":"2026091123004090000_13.11.e012243.43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7617"},{"key":"2026091123004090000_13.11.e012243.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584937","article-title":"Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function","volume":"11","author":"Alotaibi","year":"2020","journal-title":"Front Immunol"},{"key":"2026091123004090000_13.11.e012243.45","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948309"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:01:05Z","timestamp":1789192865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,29]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-012243"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012243","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}